USA - NASDAQ:TGTX - US88322Q1085 - Common Stock
The current stock price of TGTX is 34.55 USD. In the past month the price decreased by -4.36%. In the past year, price increased by 28.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.54 | 69.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014 US
CEO: Michael S. Weiss
Employees: 370
Phone: 18775758489
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
The current stock price of TGTX is 34.55 USD. The price increased by 2.55% in the last trading session.
TGTX does not pay a dividend.
TGTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
TG THERAPEUTICS INC (TGTX) operates in the Health Care sector and the Biotechnology industry.
TG THERAPEUTICS INC (TGTX) has a market capitalization of 5.48B USD. This makes TGTX a Mid Cap stock.
TG THERAPEUTICS INC (TGTX) will report earnings on 2025-10-30.
ChartMill assigns a technical rating of 4 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX turns out to be only a medium performer in the overall market: it outperformed 68.78% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to TGTX. TGTX has an average financial health and profitability rating.
Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS decreased by -38.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.31% | ||
| ROA | 8.6% | ||
| ROE | 21.87% | ||
| Debt/Equity | 0.89 |
15 analysts have analysed TGTX and the average price target is 43.18 USD. This implies a price increase of 24.98% is expected in the next year compared to the current price of 34.55.
For the next year, analysts expect an EPS growth of 451.63% and a revenue growth 83.46% for TGTX